Apogee Therapeutics (APGE) Accounts Payables (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accounts Payables data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Accounts Payables fell 49.41% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 49.41% YoY) and the FY2025 annual result came in at $1.2 million, up 14.01% from the prior year.
• Accounts Payables grew to $1.2 million in Q1 2026 per APGE's latest filing, from $1.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.1 million in Q2 2023 and bottomed at $376000.0 in Q3 2025.
• The 5-year median for Accounts Payables is $2.1 million (2023), against an average of $3.0 million.
• The widest annual swing landed in 2023, when Accounts Payables jumped 412.68%; it then tumbled 83.03% in 2025.
• Tracing APGE's Accounts Payables over 5 years: stood at $418000.0 in 2022, then jumped by 412.68% to $2.1 million in 2023, then slumped by 50.02% to $1.1 million in 2024, then advanced by 14.01% to $1.2 million in 2025, then gained by 1.31% to $1.2 million in 2026.
• Per Business Quant, the three latest APGE Accounts Payables figures stand at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $376000.0 (Q3 2025).

Peer Comparison